A new survey shows that three Big Pharmas have stolen the hearts of patient groups representing nearly 1 million people with cardiovascular conditions. | A new survey shows that three Big Pharmas have ...

Elixir Medical's DynamX bioadaptor, introduced as a potential game-changer in heart artery treatments, adapts over time to restore the artery's natural motion. A study showed it leads to fewer ...

Eli Lilly and Company LLY reported third-quarter 2024 adjusted earnings per share (“EPS”) of $1.18, which missed the Zacks ...

A new device to prop open heart arteries after interventions to unclog them adapts over time to allow restoration of the ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

Eli Lilly LLY will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for ...

Recent research from the University of Oxford reveals that individuals diagnosed with type 2 diabetes before age 40 face a ...

Lexicon's Inpefa faces fierce competition from established SGLT2 inhibitors, like Farxiga and Jardiance, making market penetration difficult. Inpefa’s early commercial results are underwhelming ...

As we were discussing what our topic should be in October, a report came across my desk about reports made by veterans and active service members to the Consumer Financial Protection Bureau (CFPB ...

Bringing up the rear in ninth and 10th places are diabetes stalwarts Novo Nordisk’s Ozempic and Eli Lilly and Boehringer Ingelheim’s treatment Jardiance, respectively. Overall spending from ...